A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

A new study aims to help healthcare providers more effectively implement Apretude, a medication used for HIV prevention.

Announced at the International AIDS Society (IAS) 2025 conference taking place from 13-17 July in Kigali, Rwanda, MSD has launched two Phase III trials, EXPrESSIVE-10 and EXPrESSIVE-11, which will ...